13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4
QUICK LINKS
PGE1 is produced by the metabolism of dihomo-γ-linolenic acid (DGLA) by the cyclooxygenase pathway. PGE1 inhibits platelet aggregation (IC50 = 40 nM) and increases vasodilation.13,14-dihydro-16,16-difluoro PGE1 is a biologically active metabolite of PGE1, inhibiting platelet aggregation with comparable potency to the parent compound. The addition of two electron-withdrawing fluorine atoms, which should stabilize the molecule against hydrolytic cleavage, may be expected to delay degradation in vivo. 13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro PGE1-3,3′,4,4′-d4) contains four deuterium atoms at the 3, 3′, 4, and 4′ positions. It is intended for use as an internal standard for the quantification of 13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1 by GC- or LC-mass spectrometry (MS).
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 References
- On the metabolism of prostaglandin E1 administered intravenously to human volunteers. | Peskar, BA., et al. 1991. J Physiol Pharmacol. 42: 327-31. PMID: 1793892
- Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin. | Hatano, Y., et al. 1980. Proc Natl Acad Sci U S A. 77: 6846-50. PMID: 7005902
- Comparison of the inhibitory effect of E-prostaglandins in human and rabbit platelet-rich plasma and washed platelets. | Kobzar, G., et al. 1993. Comp Biochem Physiol C Comp Pharmacol Toxicol. 106: 489-94. PMID: 7904921
- The effect of pulmonary metabolites of prostaglandins E1, E2 and F2alpha on ADP-induced aggregation of human and rabbit platelets [proceedings]. | Westwick, J. 1976. Br J Pharmacol. 58: 297P-298P. PMID: 974413
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4, 25 µg | sc-287299 | 25 µg | $80.00 | |||
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4, 50 µg | sc-287299A | 50 µg | $152.00 |